0.5 PPB Food Safety Rapid Test Kit Furacilin Rapid Test Card

Furacillin metabolite lateral flow assay diagnostics rapid test card Aquatic products

Overview:

The fast detection card for Furacillin (SEM) is convenient, fast and sensitive, and is suitable for on-site mass sample detection. The test card contains antigen in the test area (T) and anti-ⅱ in the control area (C) of nitrocellulose membrane fixed in advance, and gold label antibody fixed on the binding pad. According to T area, C area color contrast to determine the result. A purplish red band appeared in the C region regardless of the presence or absence of furacillin metabolites.

Detection limit:

Store in dry place at 20±5℃, do not freeze, avoid direct sunlight.

This test card is valid for 12 months, and the production date is shown in the packaging box.

Materials required but not provided:

Detection Procedure:

1. Restore the test card and sample solution to room temperature before use;

2. Take out the detection card and place it flat on the desktop;

3. Absorb the lower layer solution of the sample to be tested 80 μL, add vertically to the sample adding well;

4. 5 min after adding samples, observe the color area and determine the result.

Result Judgment:

Negative: C line color, T line darker than C line color or consistent,The test results were negative.

Positive: C line is colored, T line is lighter than C line or T line is light green, and the test result is positive.

Invalid: Line C does not display color, regardless of whether line T displays color, the detection card is judged to be invalid.

Bio key Health is a high-tech enterprise with integrating R&D, production and sales&marketing in Guangzhou. Since 2003. Bio Key was founded by the "Thousand Talents Program" entrepreneurial team and the overseas senior automation equipment development engineer team.

The company's core team has been in the field of IVD research and entrepreneurship for more than 10 years, and has mastered a wealth of molecular diagnostic POCT industrial application technology, SmartTRF immune detection technology, RT qPCR nucleic acid detection technology and independent research and development capabilities of instruments.

It has a number of independent core technologies in the fields of automation engineering, micro-precision manufacturing, immunofluorescence, nucleic acid detection and gene sequencing. Since its establishment, the company has applied for more than 60 patents and currently has 17 authorized patents. The company has two R&D centers for diagnostic reagents and instruments and equipment, totaling more than 500 square meters; it has established more than 2,000 square meters of GMP workshops and equipment production plants; it has SmartTRF new immune detection technology, nucleic acid detection technology (POCT) and three scientific services.